Bigfoot Biomedical offers healthcare support to patients with type 1 and type 2 diabetes by reducing the complexity of insulin dose and delivery using a smartphone-enabled system.
The company has seen strong uptake following its FDA clearance, as its subscription model offers an attractively cost-efficient way of managing care expenses and logistics. Its business model uniquely centres around reimbursement, as the use of specific billing codes for Remote Physiologic Monitoring (RPM) makes this method of billing far simpler for providers.
An attractive proposition for healthcare providers and diabetic patients alike, the progress of this novel solution is likely to be keenly watched by the industry. It is improving its systems and products for both type 1 and type 2 diabetes, and its recent acquisition of an insulin titration algorithm developed at McGill University will allow it to better observe how its customers respond to particular insulin doses and adjust them accordingly.
Freddie
Company Specialist at Welcome to the Jungle